Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment Article

cited authors

  • Ao, Wei; Kim, Hong Im; Tommarello, Domenic; Conrads, Kelly A.; Hood, Brian L.; Litzi, Tracy; Abulez, Tamara; Teng, Pang-Ning; Dalgard, Clifton L.; Zhang, Xijun; Wilkerson, Matthew D.; Darcy, Kathleen M.; Tarney, Christopher M.; Phippen, Neil T.; Bakkenist, Christopher J.; Maxwell, G. Larry; Conrads, Thomas P.; Risinger, John I.; Bateman, Nicholas W.

authors

Publication Date

  • August 26, 2023

webpage

published in

category

keywords

  • (CDC25A)
  • ATR
  • Ataxia telangiectasia and Rad3-related
  • Cell division cycle 25A
  • Checkpoint kinase 1
  • Chk1
  • Drug resistance
  • Ovarian cancer

start page

  • 60

end page

  • 71

volume

  • 177